Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study-Reference-Cited by-同舟云学术

Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Published:2024-04 Issue:2 Volume:22 Page:458-466.e1
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Kafka Mona,Giannini Giulia,Artamonova Nastasiia,Neuwirt Hannes,Ofner Heidemarie,Kramer Gero,Bauernhofer Thomas,Luger Ferdinand^ORCID,Höfner Thomas,Loidl Wolfgang,Griessner Hubert,Lusuardi Lukas^ORCID,Bergmaier Antonia,Berger Andreas,Winder Thomas,Weiss Sarah,Bauinger Severin,Krause Steffen,Drerup Martin,Heinrich Elmar,Schneider Magdalena,Madersbacher Stephan,Vallet Sonia,Stoiber Franz,Laimer Sarah,Hruby Stephan,Schachtner Gert,Nagele Udo,Lenart Sebastian^ORCID,Ponholzer Anton,Pfuner Jacob^ORCID,Wiesinger Clemens,Kamhuber Christoph,Müldür Ecan,Bektic Jasmin,Horninger Wolfgang,Heidegger Isabel

Funder

Medizinische Universitat Innsbruck

Publisher

Elsevier BV

Reference22 articles.

1. Androgen signaling in prostate cancer;Dai;Cold Spring Harb Perspect Med,2017

2. The androgen/androgen receptor axis in prostate cancer;Bluemn;Curr Opin Oncol,2012

3. Aldo-keto reductase (AKR) 1C3 inhibitors: a patent review;Penning;Expert Opin Ther Pat,2017

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Novel steroidal inhibitors of human cytochrome P45017.alpha.-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer;Potter;J Med Chem,1995

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

2. Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study;Japanese Journal of Clinical Oncology;2024-07-22